Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia 1

Interventions

Cyclophosphamide 46fludarabine phosphate 40Tacrolimus 36Busulfan 34Peripheral Blood Stem Cell Transplantation 31Whole-Body Irradiation 29Mycophenolic Acid 27Antilymphocyte Serum 23Methotrexate 22Azacitidine 21Cyclosporine 20Cytarabine 17Melphalan 16Decitabine 16Radiotherapy 14fludarabine 13Methylprednisolone 12Filgrastim 12Cord Blood Stem Cell Transplantation 10Stem Cell Transplantation 8Etoposide 8Biopsy 8venetoclax 7Specimen Handling 7Rituximab 7Injections 7Arsenic Trioxide 7thymoglobulin 6merphos 6Sirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelomonocytic, Chronic × glasdegib × Clear all
NCT01842646 2021-06-14

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
35 enrolled 7 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡